Group 1 - The stock price of Tianxin Pharmaceutical (603235) has shown volatility in the past week, closing at 27.21 yuan on February 12, 2026, with a decrease of 0.98% on that day and a trading volume of 15.16 million yuan, indicating short-term pressure on capital flow [1] - Over the past five days, the cumulative increase in stock price is 1.08%, but on February 12, there was a net outflow of 518,900 yuan from main funds, suggesting a challenging short-term funding environment [1] - The stock is currently near a 20-day resistance level of 27.57 yuan, with the Bollinger Band's middle track at 27.11 yuan, and the KDJ indicator's J line at 82.58, indicating a high position that requires attention to momentum changes after breaking the resistance level [1] Group 2 - The company's Q3 2025 financial report shows a revenue of 1.631 billion yuan for the first three quarters, representing a year-on-year growth of 1.08%, while the net profit attributable to shareholders is 460 million yuan, reflecting a year-on-year decrease of 6.91% [2] - In Q3 alone, revenue was 509 million yuan, down 7.02% year-on-year, with the net profit decline expanding to 30.15%, primarily due to fluctuations in vitamin industry demand and cost pressures [2] - The gross profit margin remains at 45.34%, but the net profit margin has narrowed [2] Group 3 - Institutional attention towards Tianxin Pharmaceutical has been low recently, with only one institution giving a "buy" rating in the last 90 days [3] - Institutions focus on the company's global market share advantages in Vitamin B6 and B1, which are leading positions, and the overseas revenue proportion of 51.52% that benefits from the depreciation of the yuan [3] - However, there is a need to be cautious about intensified industry competition that may challenge the sustainability of profitability [3]

Core Viewpoint - The announcement details the expected daily related transactions for Jiangxi Tianxin Pharmaceutical Co., Ltd. in 2026, emphasizing that these transactions will not affect the company's independence or financial stability [2][32]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2026 on January 26, 2026, with a voting result of 6 in favor and 0 against [2][4]. - The expected total amount for daily related transactions in 2026 is capped at 68.4725 million RMB [8]. - The transactions include services such as processing vitamin E powder and providing meeting services, as well as leasing properties for employee accommodation [8][31]. Group 2: Impact and Compliance - The independent directors reviewed the proposal on January 22, 2026, and unanimously agreed that the transactions align with the company's business development and do not harm the interests of shareholders, particularly minority shareholders [4][32]. - The company asserts that these transactions are normal business activities and are conducted at market prices, ensuring fairness and compliance with relevant laws and regulations [31][32]. Group 3: Related Parties - The related parties involved include Zhejiang Xinweishi Biotechnology Co., Ltd., Qi Shan Tiancheng Vinegar Industry Co., Ltd., and Shanghai Nuirui Biotechnology Co., Ltd., all of which are under the indirect control of the company's actual controller, Xu Jiangnan [10][11][13][14]. - The announcement provides detailed information about the related parties, including their registration details, capital structure, and business scope [10][11][13][14].

江西天新药业股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易的基本情况 证券代码：603235 证券简称：天新药业 公告编号：2026-002 （一）日常关联交易履行的审议程序 1、董事会审议情况 公司于 2026 年 1 月 26 日召开第三届董事会第十三次会议，审议通过了 《关于 2026 年度日常关联交易预计的议案》，董事会在对该关联交易议案进行 表决时，关联董事许江南、许晶、王光天对该议案回避表决，其他参与表决的 非关联董事以 6 票同意、0 票反对、0 票弃权的表决结果审议通过了该项议案。 鉴于公司 2026 年度日常关联交易的预计额度在董事会决策权限内，该议案 无需提交股东会审议。 2、独立董事专门会议审议情况 在董事会审议前，公司独立董事于 2026 年 1 月 22 日召开的第三届董事会 第三次独立董事专门会议对上述议案进行了审核，以 3 票同意、0 票反对、0 票 是否需要提交股东会审议：否 日常关联交易对上市公司的影响 ...

Group 1 - The sixth Asian Beach Games will hold a press conference on January 12, 2023, to discuss the preparation status [2] - Shanghai Disneyland will implement a tiered refund policy starting January 12, 2026, allowing full refunds up to 7 days before the visit [3] - A total of 9 companies will have their restricted shares unlocked on January 12, with a total unlock volume of 742 million shares, valued at 17.761 billion [4] Group 2 - One company has disclosed its stock repurchase progress, with BOE Technology Group completing a repurchase amounting to 1.5 billion [5] - Seven A-shares will undergo equity registration on January 12, with significant dividends announced, including Hai Kan Co. distributing 5.20 yuan per 10 shares [6] - Economic data such as the Eurozone Sentix Investor Confidence Index and India's CPI for December 2025 will be released [7]

Group 1 - On January 12, a total of 4 listed companies had their restricted shares unlocked, with a total market value of approximately 6.055 billion yuan [1] - The specific details of the restricted share unlocks are as follows: [1] - Zhongbai Group (Stock Code: 000759) had 7.3776 million shares unlocked under equity incentive restrictions [1] - Xianghe Industrial (Stock Code: 603500) had 554,000 shares unlocked under equity incentive restrictions [1] - Tianxin Pharmaceutical (Stock Code: 603235) had 263 million shares unlocked with an extended lock-up period [1] - Fulei New Materials (Stock Code: 605488) had 40,000 shares unlocked under equity incentive restrictions [1]

Market News - China will release December import and export data on January 14, with exports expected to grow by 3.0% year-on-year, down from 5.9% in November, while imports are anticipated to decline by 2.9% [3] - The trade balance for December 2025 will also be published on January 14, with total goods trade from January to November 2025 reaching 41.21 trillion yuan, a year-on-year increase of 3.6% [3] Commodity Futures - The Shanghai Futures Exchange will adjust the price limit for platinum and palladium futures contracts to 16% starting from January 13, 2026, with the trading margin standard set at 18% [4] Energy Outlook - The U.S. Energy Information Administration (EIA) will release its Short-Term Energy Outlook report on January 13, maintaining the WTI crude oil price forecast for 2025 at slightly below $69 per barrel [5] U.S. Economic Data - The U.S. will release December CPI data on January 13, with core CPI expected to rebound significantly, predicted at 0.36% by Morgan Stanley and 0.38% by Bloomberg, both higher than the average of 0.08% in October and November [6] - Key economic indicators including October and November PPI and November retail sales will also be released, with expectations of moderate PPI growth and a 0.7% rebound in retail sales for November [6] Federal Reserve - The Federal Reserve will publish its latest Beige Book on January 14, indicating that government shutdowns and AI applications have weakened the job market, while rising tariffs and healthcare costs have increased business expenses [7] Earnings Season - The earnings season for Q4 2025 will commence this week, with major banks including JPMorgan, Citigroup, and Goldman Sachs set to report [8] Sector Events - The second China eVTOL Innovation Development Conference is scheduled for January 15-16, 2026, in Shanghai, focusing on the new commercial era of eVTOL [10] - The fourth Data Center Liquid Cooling & AI Chip Thermal Management Supply Chain Conference will be held on January 14-15, 2026, in Shenzhen [10] - China's first comprehensive law in the nuclear energy sector, the Atomic Energy Law, will take effect on January 15, 2026 [11] Individual Company News - Hangyu Technology announced on January 11 that it has repurchased 752,800 shares, with plans to sell them within six months [13] - Huadong Medicine's subsidiary has developed a breakthrough treatment for severe hypertriglyceridemia, which has been included in the list of breakthrough therapies by the National Medical Products Administration [13] - Jingfeng Mingyuan plans to acquire 100% of Sichuan Yichong Technology Co., with a key review meeting scheduled for January 16, 2026 [13] - TSMC has commenced research on its next-generation 1.4nm process, with risk trial production expected to start in 2027 [13] Lock-up Expiration - From January 12 to January 16, 2026, 23 companies will have lock-up shares released, totaling 2.434 billion shares with a market value of approximately 48.56 billion yuan [16] - The highest market value of lock-up shares released on January 12 is from Tianxin Pharmaceutical at 7.84 billion yuan [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total issuance of approximately 34 million shares and expected fundraising of 1.909 billion yuan [19] Market Outlook - The current market enthusiasm is driven by concentrated inflows from previously cautious funds, with expectations for continued momentum in thematic and small-cap stocks until after the Two Sessions [22] - Guojin Securities suggests that the spring market is likely to perform well, with a focus on AI investments and the recovery of domestic manufacturing [23] - Everbright Securities anticipates sustained market heat but warns of potential cooling as the Lunar New Year approaches, recommending attention to sectors like electronics and power equipment [24]

Group 1 - The core point of the news is that Jiaoyun Co., Ltd. is planning a significant asset swap involving its passenger car sales and automotive after-service segments with assets related to the cultural and entertainment industry held by its controlling shareholder, Jiushi Group, and its affiliates [1] - The transaction is expected to constitute a major asset restructuring, with the price difference between the assets to be settled in cash [1] - The transaction price has not yet been determined [1] Group 2 - On January 9, Jiaoyun Co., Ltd. closed at the daily limit, with a total market value of 6.983 billion yuan [2] - Next week, a total of 23 stocks will have their shares unlocked, amounting to 2.434 billion shares, with a total unlock market value of 48.556 billion yuan based on the latest closing prices [5] - Among the stocks with significant unlock pressure, Zhongke Lanyun is expected to have the highest unlock market value at 11.087 billion yuan, followed by Tianxin Pharmaceutical at 7.841 billion yuan [6][7]

Core Viewpoint - Jiangxi Tianxin Pharmaceutical Co., Ltd. is set to list 290,714,800 restricted shares for trading on January 12, 2026, following the expiration of the lock-up period for these shares [2][4][6]. Group 1: Stock Listing Details - The total number of shares to be listed is 290,714,800 [3][14]. - The shares being listed are part of the company's initial public offering (IPO) and were approved by the China Securities Regulatory Commission on June 13, 2022 [5]. - The IPO involved issuing 43.78 million shares at a price of 36.88 yuan per share, resulting in a total share capital of 437,780,000 shares, with 394,000,000 shares subject to trading restrictions [5]. Group 2: Shareholder Information - The restricted shares are held by five shareholders, including Xu Jiangnan and Xu Jing, who collectively own 262,714,800 shares, which will have their lock-up period extended by 6 months due to commitments made during the IPO [6]. - The total restricted shares represent 66.41% of the company's total share capital [6]. Group 3: Lock-up Commitments - Shareholders have made commitments regarding the lock-up period, including not transferring shares during the initial 36 months and adhering to specific conditions for any future share sales [8][10][11]. - If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period will automatically extend for at least 6 months [9]. Group 4: Compliance and Verification - The underwriter, CITIC Securities Co., Ltd., has confirmed that the shareholders have complied with their commitments regarding the restricted shares [13]. - There are no reported instances of fund occupation by controlling shareholders or related parties [12].

证券代码：603235 证券简称：天新药业 公告编号：2026-001 江西天新药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 290,714,800股。 三、本次限售股上市流通的有关承诺 根据《江西天新药业股份有限公司首次公开发行股票招股说明书》，本次解 除股份限售的股东就股份锁定事宜承诺如下： （一）公司控股股东、实际控制人许江南及实际控制人许晶承诺： 本次股票上市流通总数为290,714,800股。 本次股票上市流通日期为2026 年 1 月 12 日。 一、本次限售股上市类型 江西天新药业股份有限公司（以下简称"公司"）经中国证券监督管理委员 会于 2022 年 6 月 13 日出具的《关于核准江西天新药业股份有限公司首次公开发 行股票的批复》（证监许可〔2022〕1220 号）的核准，公司首次公开发行人民币 普通股（A 股）4,378 万股，每股面值 1.00 元，每股发行价格 ...

中信证券股份有限公司 关于江西天新药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江西天 新药业股份有限公司（以下简称"天新药业"或"公司"）首次公开发行股票并 上市的保荐人，根据《首次公开发行股票注册管理办法》《证券发行上市保荐业 务管理办法》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等有关规定，对天新药业首次 公开发行部分限售股上市流通的事项进行了专项核查，核查情况如下： 一、本次限售股上市类型 天新药业经中国证券监督管理委员会于 2022 年 6 月 13 日出具的《关于核准 江西天新药业股份有限公司首次公开发行股票的批复》（证监许可〔2022〕1220 号）的核准，公司首次公开发行人民币普通股（A 股）4,378 万股，每股面值 1.00 元，每股发行价格 36.88 元，公司股票于 2022 年 7 月 12 日起在上海证券交易所 上市交易。首次公开发行后，公司总股本为 437,780,000 股，其中有限售条件的 流通股为 394,000,000 股 ...